209853-25-8Relevant articles and documents
Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes
Asquith, Christopher R. M.,Awad, Dominik,Catta-Preta, Carolina M. C.,Cou?ago, Rafael M.,Drewry, David H.,Eduful, Benjamin J.,Frigo, Daniel E.,Hossain, Mohammad Anwar,Langendorf, Christopher G.,Liang, Yi,Lin, Chenchu,Nay, Kévin,O'Byrne, Sean N.,Oakhill, Jonathan S.,Picado, Alfredo,Pilotte, Joseph R.,Pulliam, Thomas L.,Santiago, André De S.,Scott, John W.,Temme, Louisa,Wells, Carrow I.,Willson, Timothy M.,Zonzini Ramos, Priscila,Zuercher, William J.
, p. 10849 - 10877 (2021/08/03)
CAMKK2 is a serine/threonine kinase and an activator of AMPK whose dysregulation is linked with multiple diseases. Unfortunately, STO-609, the tool inhibitor commonly used to probe CAMKK2 signaling, has limitations. To identify promising scaffolds as starting points for the development of high-quality CAMKK2 chemical probes, we utilized a hinge-binding scaffold hopping strategy to design new CAMKK2 inhibitors. Starting from the potent but promiscuous disubstituted 7-azaindole GSK650934, a total of 32 compounds, composed of single-ring, 5,6-, and 6,6-fused heteroaromatic cores, were synthesized. The compound set was specifically designed to probe interactions with the kinase hinge-binding residues. Compared to GSK650394 and STO-609, 13 compounds displayed similar or better CAMKK2 inhibitory potency in vitro, while compounds 13g and 45 had improved selectivity for CAMKK2 across the kinome. Our systematic survey of hinge-binding chemotypes identified several potent and selective inhibitors of CAMKK2 to serve as starting points for medicinal chemistry programs.
INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR
-
Page/Page column 32; 34, (2009/03/07)
The present invention relates to indolylalkylthienopyhmidylamines of the general formula (I), to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP2
Evolution of the thienopyridine class of inhibitors of IκB kinase-β: Part I: Hit-to-lead strategies
Morwick, Tina,Berry, Angela,Brickwood, Janice,Cardozo, Mario,Catron, Katrina,DeTuri, Molly,Emeigh, Jonathan,Homon, Carol,Hrapchak, Matt,Jacober, Stephen,Jakes, Scott,Kaplita, Paul,Kelly, Terence A.,Ksiazek, John,Liuzzi, Michel,Magolda, Ronald,Mao, Can,Marshall, Daniel,McNeil, Daniel,Prokopowicz II, Anthony,Sarko, Christopher,Scouten, Erika,Sledziona, Cynthia,Sun, Sanxing,Watrous, Jane,Wu, Jiang Ping,Cywin, Charles L.
, p. 2898 - 2908 (2007/10/03)
High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IκB kinase-β (IKKβ), a key regulatory enzyme in the nuclear factor-κB (NF-κB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.